Inari Medical, Inc. NARI
We take great care to ensure that the data presented and summarized in this overview for Inari Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NARI
View all-
Black Rock Inc. New York, NY8.36MShares$464 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$310 Million0.0% of portfolio
-
Hcc Manager LLC Chicago, IL2.91MShares$162 Million91.04% of portfolio
-
Alliancebernstein L.P. New York, NY2.15MShares$119 Million0.03% of portfolio
-
State Street Corp Boston, MA2.04MShares$113 Million0.0% of portfolio
-
Brown Advisory Inc1.83MShares$101 Million0.1% of portfolio
-
Armistice Capital, LLC New York, NY1.82MShares$101 Million1.25% of portfolio
-
Jennison Associates LLC1.58MShares$87.4 Million0.04% of portfolio
-
Vestal Point Capital, LP New York, NY1.55MShares$85.9 Million4.85% of portfolio
-
Credit Suisse Ag Zurich, V81.29MShares$71.3 Million0.06% of portfolio
Latest Institutional Activity in NARI
Top Purchases
Top Sells
About NARI
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Insider Transactions at NARI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2024
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.34%
|
$165,000
$55.43 P/Share
|
|
Dec 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
60,000
-1.57%
|
$3,300,000
$55.74 P/Share
|
|
Dec 10
2024
|
Thomas Tu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,000
-1.3%
|
$220,000
$55.0 P/Share
|
|
Dec 01
2024
|
Karen Silva Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,215
+50.0%
|
-
|
|
Nov 20
2024
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.67%
|
$150,000
$50.83 P/Share
|
|
Nov 18
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
60,000
-2.21%
|
$3,060,000
$51.06 P/Share
|
|
Oct 29
2024
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.67%
|
$150,000
$50.0 P/Share
|
|
Oct 29
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,000
-3.38%
|
$2,000,000
$50.05 P/Share
|
|
Oct 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,000
-3.16%
|
$1,800,000
$45.17 P/Share
|
|
Oct 01
2024
|
Kevin T Strange Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,041
-0.36%
|
$41,640
$40.63 P/Share
|
|
Oct 01
2024
|
Kevin T Strange Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,695
+10.53%
|
-
|
|
Oct 01
2024
|
Andrew Hykes President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,222
-0.23%
|
$168,880
$40.63 P/Share
|
|
Oct 01
2024
|
Thomas Tu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,120
-0.17%
|
$84,800
$40.63 P/Share
|
|
Oct 01
2024
|
William Hoffman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,063
-0.16%
|
$82,520
$40.63 P/Share
|
|
Oct 01
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,067
-0.29%
|
$82,680
$40.63 P/Share
|
|
Sep 16
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
40,000
-2.95%
|
$1,840,000
$46.0 P/Share
|
|
Sep 12
2024
|
Hill, Mitch C. Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-0.55%
|
$135,000
$45.51 P/Share
|
|
Sep 12
2024
|
Hill, Mitch C. Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+1.62%
|
$0
$0.46 P/Share
|
|
Aug 20
2024
|
Andrew Hykes President and CEO |
SELL
Open market or private sale
|
Direct |
3,000
-0.66%
|
$150,000
$50.0 P/Share
|
|
Aug 19
2024
|
William Hoffman Director |
SELL
Open market or private sale
|
Direct |
20,000
-2.84%
|
$1,000,000
$50.3 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 118K shares |
|---|---|
| Exercise of conversion of derivative security | 36K shares |
| Payment of exercise price or tax liability | 41.2K shares |
|---|---|
| Open market or private sale | 682K shares |